Jacobs Levy Equity Management, Inc Alnylam Pharmaceuticals, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q1 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 152,970 shares of ALNY stock, worth $52 Million. This represents 0.17% of its overall portfolio holdings.
Number of Shares
152,970Holding current value
$52 Million% of portfolio
0.17%Shares
13 transactions
Others Institutions Holding ALNY
# of Institutions
724Shares Held
111MCall Options Held
966KPut Options Held
853K-
Capital World Investors Los Angeles, CA16.7MShares$5.69 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$4.44 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$3.24 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$2.43 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.5 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $41.8B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...